- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06054815
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed Non-alcoholic Steatohepatitis (NASH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Clinical trial DA1241_NASH_IIa is a multicenter, randomized, double-blind, placebo-controlled, parallel-arm, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed NAFLD.
Part 1 of this clinical trial intends to explore the efficacy of DA-1241 in subjects with NASH after administration of oral DA-1241 at varying doses or identical placebo in 3 treatment groups for 16 weeks/112 days.
Part 2 intends to explore the efficacy of DA-1241 in subjects with NASH after administration of oral DA-1241 in combination with sitagliptin versus an identical placebo for 16 weeks/112 days.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Robert Homolka
- Phone Number: (917) 633-6086
- Email: CRInfo@neurobopharma.com
Study Contact Backup
- Name: Ji Eun Lee
- Phone Number: (917) 633-6086
- Email: CRInfo@neurobopharma.com
Study Locations
-
-
California
-
Coronado, California, United States, 92118
- Recruiting
- Southern California Research Center
-
Montclair, California, United States, 91763
- Recruiting
- Catalina Research Institute, LLC
-
Panorama City, California, United States, 91402
- Recruiting
- Velocity Clinical Research, Panorama City
-
Rialto, California, United States, 92377
- Recruiting
- Inland Empire Clinical Trials, LLC
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Recruiting
- Excel Medical Trials
-
Doral, Florida, United States, 33122
- Recruiting
- Integrity Clinical Research, LLC
-
Lady Lake, Florida, United States, 32159
- Recruiting
- Lake Center for Clinical Research
-
Miami, Florida, United States, 33014
- Recruiting
- Clinical Pharmacology of Miami, LLC
-
Miami, Florida, United States, 33135
- Recruiting
- Suncoast Research Group, LLC
-
Miami Lakes, Florida, United States, 33016
- Recruiting
- Floridian Clinical Research
-
Ocoee, Florida, United States, 34761
- Recruiting
- Sensible Healthcare, LLC
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- Recruiting
- Kansas Medical Clinical, PA
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Recruiting
- Tandem Clinical Research GI, LLC
-
-
Mississippi
-
Flowood, Mississippi, United States, 39232
- Recruiting
- GI Associates & Endoscopy Center
-
-
New Jersey
-
Florham Park, New Jersey, United States, 07932
- Recruiting
- AIG Digestive Disease Research
-
-
New York
-
New York, New York, United States, 10033
- Recruiting
- Tandem Clinical Research GI, LLC
-
-
Texas
-
Edinburg, Texas, United States, 78539
- Recruiting
- South Texas Research Institute - A Pinnacle Entity
-
Farmers Branch, Texas, United States, 75234
- Recruiting
- Dallas Research Institute, LLC
-
Georgetown, Texas, United States, 78626
- Recruiting
- Pinnacle Clinical Research - Georgetown
-
Houston, Texas, United States, 77099
- Recruiting
- Pioneer Research Solutions Inc.
-
San Antonio, Texas, United States, 78229
- Recruiting
- Pinnacle Clinical Research - San Antonio
-
San Antonio, Texas, United States, 78215
- Recruiting
- American Research Corporation
-
San Antonio, Texas, United States, 78258
- Recruiting
- Apex Mobile Clinical Research, LLC
-
San Marcos, Texas, United States, 78666
- Recruiting
- Texas Digestive Disease Consultants - San Marcos
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Liver Institute Northwest
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Subjects who are able to understand and sign informed consent before the conduct of any protocol specific screening procedures.
- Subjects who are male or female, aged 18 to 75 years inclusive at the time of consent.
Female subjects of childbearing potential:
- Must agree to abide by contraception requirements, must not be lactating, and avoid pregnancy during study participation from the first Screening visit until 30 days after the last dose of study drug.
Must commit to an additional method of birth control in addition to male partners agreeing to use condoms with spermicide, throughout the study including for at least 30 days after the last dose of the study drug:
- True abstinence: Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence [eg, calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable).
- Combined (containing estrogen and progestogen) hormonal birth control (oral, intravaginal, injectable, or transdermal) associated with inhibition of ovulation initiated at least 30 days before dose administration.
- Progestogen only hormonal birth control (oral, injectable, or implantable) associated with inhibition of ovulation initiated at least 30 days before study dose administration.
- Bilateral tubal occlusion/ligation.
- Intrauterine device (IUD).
- Intrauterine hormone releasing system (IUS).
- Vasectomized partner.
Female subjects of non-childbearing potential do not need to use birth control during or after study drug treatment if considered of non-childbearing potential due to any of the following criteria:
Premenopausal female with permanent sterility or permanent infertility as due to one of the following:
- Permanent sterility due to a hysterectomy, bilateral salpingectomy, bilateral oophorectomy.
- Non-surgical permanent infertility due to Mullerian agenesis, androgen insensitivity, or gonadal dysgenesis; Investigator discretion should be applied to determining study entry for these individuals.
- Postmenopausal female subjects, with no menses for 12 or more months without an alternative medical cause AND a follicle stimulating hormone (FSH) level ≥ 40 IU/L.
- Male subjects who are sexually active with a female partner of childbearing potential must agree to use male condoms and spermicide, even if the male subject has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last dose of the study drug.
- Subjects with a BMI > 23 kg/m2 at first Screening Period visit.
- Subjects with a qualifying ALT result (40 IU/L ≤ ALT < 200 IU/L) as determined by the laboratory assessment at the first Screening Period visit.
- Subjects with a confirmed NASH diagnosis or conditions consistent with NASH.
- Subjects with an HbA1c ≥ 5.7% and < 9.5% (5.7% ≤ HbA1c < 9.5%).
- Subjects with ≥ 8% hepatic fat on MRI after confirming a qualifying ALT result at Screening.
- Subjects with CAP score by FibroScan® of ≥ 290 dB/m at the time of the first Screening Period visit.
- Subjects with 7 kPa ≤ VCTE score by FibroScan® < 14 kPa at the time of the first Screening Period visit.
For subjects receiving stable doses of the following medications prior to the first Screening Period visit, the following conditions applied:
- Sodium-glucose cotransporter-2 (SGLT-2): no dose changes for at least 12 weeks prior to the first Screening Period visit.
- Insulin and oral antidiabetic medications or drugs for dyslipidemia: no dose changes for at least 8 weeks prior to the first Screening Period visit; defined as a change of no more than a ± 25% in total daily dose of insulin during this period.
- Vitamin E > 400 I/U: daily dose of ≤ 800 I/U, stable for at least 12 weeks prior to the first Screening Period visit.
- HMG-CoA Reductase Inhibitor (statins): no dose changes for at least 8 weeks prior to the first Screening Period visit.
Exclusion Criteria
- Subjects who have used an investigational agent within 30 days or 5 elimination half-lives; whichever is longer prior to the first Screening Period visit.
- Subjects diagnosed with liver disease other than NASH (eg, chronic viral hepatitis, decompensated cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, α-1-antitrypsin deficiency, primary biliary cholangitis, drug-induced liver disease).
- Subjects who have a positive test result for hepatitis A virus immunoglobulin M, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or reactive human immunodeficiency virus (HIV) after providing a qualifying ALT result at the first Screening Period visit, or who have a known history of HIV infection. However, subjects with a positive hepatitis C virus antibody could be eligible after undergoing reflex testing (HCV-RNA negative) and evaluation by the Investigator.
Clinically significant laboratory results as evaluated by the Investigator after providing a qualifying ALT result at the first Screening Period visit. Subjects will be excluded if:
- AST ≥ 200 U/L
- Platelets ≤ 150,000/mm3
- Albumin < 3.8 g/dL
- Total bilirubin ≥ 1.5 mg/dl, except with clinical diagnosis of Gilbert's syndrome
- Direct bilirubin > 0.3 mg/dL
- Phosphatidylethanol > 40 ng/mL
- INR > 1.3 in the absence of anticoagulants
- Subjects with an estimated glomerular filtration rate < 60 mL/min/1.73m2 based on modification of Diet in Renal Disease (MDRD) formula.
- Subjects with a corrected QT interval by Fridericia (QTcF) of > 450 ms in males, and > 470 ms in females.
Subjects who are taking one or more of the following medications:
- Within 12 weeks prior to the first Screening Period visit: i. Medication that is known to cause or worsen fatty liver disease (amiodarone, valproate, tamoxifen, methotrexate, etc.) for > 14 days. ii. Medication for weight loss. iii. Chronic use of systemic corticosteroids for > 14 days; however, administration of intranasal, topical, or inhaled corticosteroids is allowed. iv. DPP-4 inhibitors, thiazolidinediones (TZDs), or GLP-1 agonists.
- St. John's Wort or consuming grapefruit juice within 2 weeks prior to the first Screening Period visit.
- Digoxin, strong CYP3A4 inhibitors (a ≥ 10-fold increase in AUC of sensitive substrate), or strong CYP3A4 inducers (decreases the AUC of sensitive index substrates of a given metabolic pathway ≥ 80% increase) received within 5 half-lives or 14 days (whichever is longer) prior to the first Screening Period visit.
- Subjects who cannot get an MRI scan.
- Subjects who have a history of cirrhosis, a VCTE ≥ 14 kPa, portal hypertension as evidenced by a history of splenomegaly > 15 cm, ascites, hepatic encephalopathy, varices on imaging/endoscopy or history of variceal bleeding, or a Model for End Stage Liver Disease (MELD) score > 10.
- Subjects who have undergone bariatric surgery within 5 years prior to the first Screening Period visit after confirming a qualifying ALT result or are planning bariatric surgery during the clinical trial.
- Subjects with a history of malignancy within 2 years prior to the first Screening Period visit. However, subjects who have completed all cancer therapies with no evidence of active malignancy within the 2 years prior to the first Screening Period visit will be allowed, except for squamous cell or basal cell carcinoma of the skin definitively treated > 12 weeks prior to the first Screening Period visit.
- Subjects who have a presence of clinically significant cardiac (including Grade III/IV heart failure as defined by the New York Heart Association Criteria [Appendix 10.2]). This includes subjects with a history of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 90 days prior to the first Screening Period visit.
- Subjects with a history of acute cardiovascular disease (uncontrolled arrhythmia, unstable angina, myocardial infarction, stroke, transient ischemic attack, cerebrovascular disease, etc.) within 12 weeks prior to the first Screening Period visit.
- Subjects with a history of drug abuse or alcohol addiction within 12 weeks prior to the first Screening Period visit.
- Subjects with a positive screen for drugs of abuse (ie, amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiate metabolite, and phencyclidine). Subjects who have been prescribed benzodiazepine or opiates for stable chronic medical illness may still qualify for the study at the discretion of the Investigator and review of the Medical Monitor.
- Subjects who have physical (severe disorders in liver, heart, kidney, lung, blood, endocrine system, musculoskeletal system, gastrointestinal system, etc.) or mental (cognitive impairment, mental illness) conditions that may affect the subject's ability to participate in the clinical trial.
- If female, subjects who are pregnant or lactating or intend to become pregnant during the clinical trial.
- If male, subjects who intend to impregnate a partner.
- Subjects who intend to donate ova or sperm during the clinical trial.
- Subjects with known or suspected intolerance or hypersensitivity to IPs, closely-related compounds, or any of the stated ingredients.
- Subjects with a weight change of > 10% measured at the first Screening Period and TP1 visits.
- Subjects who cannot communicate reliably with the Investigator or are unlikely to cooperate with the requirements of the clinical trial.
- Subjects with any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in, or completion of, the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1 Group 1
DA-1241 Dose 1 In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio. |
Route of Administration: Oral, with subjects in a fasting state
Route of Administration: Oral, with subjects in a fasting state
Route of Administration: Oral, with subjects in a fasting state
|
Experimental: Part 1 Group 2
DA-1241 Dose 2 In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio. |
Route of Administration: Oral, with subjects in a fasting state
Route of Administration: Oral, with subjects in a fasting state
|
Placebo Comparator: Part 1 Group 3.1
DA-1241 Placebo and Sitagliptin Placebo In Part 1: Participants will be randomized into 3 treatment groups and will be dosed with: DA-1241 or placebo in a 1:2:1 ratio. |
Route of Administration: Oral, with subjects in a fasting state
Route of Administration: Oral, with subjects in a fasting state
|
Placebo Comparator: Part 2 Group 3.2
DA-1241 Placebo and Sitagliptin Placebo In Part 2: Participants will be randomized into 2 treatment groups and will be dosed with: DA-1241 in combination with sitagliptin (DA-1241/sitagliptin) or DA-1241/ sitagliptin placebo in a 2:1 ratio. |
Route of Administration: Oral, with subjects in a fasting state
Route of Administration: Oral, with subjects in a fasting state
|
Experimental: Part 2 Group 4
DA-1241 and Sitagliptin In Part 2: Participants will be randomized into 2 treatment groups and will be dosed with: DA-1241 in combination with sitagliptin (DA-1241/sitagliptin) or DA-1241/ sitagliptin placebo in a 2:1 ratio. |
Route of Administration: Oral, with subjects in a fasting state
Route of Administration: Oral, with subjects in a fasting state
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change alanine transaminase (ALT) levels
Time Frame: Baseline to Day 112
|
To explore the efficacy (change from baseline in alanine transaminase [ALT]) of DA-1241 in subjects at risk of NASH or subjects with non-alcoholic fatty liver disease (NAFLD) after administration of oral DA-1241 at varying doses of placebo and in combination with sitagliptin.
|
Baseline to Day 112
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ALT Normalization
Time Frame: Baseline to Day 112
|
Proportion of subjects with normalization of ALT: < 30 IU/L
|
Baseline to Day 112
|
AST, GGT, ALP
Time Frame: Baseline to Day 112
|
Absolute change in aspartate transaminase (AST), gamma glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP).
|
Baseline to Day 112
|
Total cholesterol, LDL, HDL, triglyceride, and free fatty acids
Time Frame: Baseline to Day 112
|
Absolute change in total cholesterol, low and high-density lipoprotein cholesterol, triglyceride, and free fatty acids from baseline.
|
Baseline to Day 112
|
A1c
Time Frame: Baseline to Day 112
|
Absolute change in hemoglobin A1c (HbA1c) (%).
|
Baseline to Day 112
|
Glucose
Time Frame: Baseline to Day 112
|
Absolute change in fasting plasma glucose (mg/dL).
|
Baseline to Day 112
|
Fasting insulin
Time Frame: Baseline to Day 112
|
Absolute change in fasting insulin.
|
Baseline to Day 112
|
HOMA-IR
Time Frame: Baseline to Day 112
|
Absolute change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).
|
Baseline to Day 112
|
Adipo-IR
Time Frame: Baseline to Day 112
|
Absolute change in adipose tissue insulin resistance index (adipo-IR).
|
Baseline to Day 112
|
CAP
Time Frame: Baseline to Day 112
|
Absolute change in controlled attenuation parameter (CAP) score assessed by FibroScan®.
|
Baseline to Day 112
|
VCTE
Time Frame: Baseline to Day 112
|
Absolute change in vibration-controlled transient elastography (VCTE) score assessed by FibroScan®.
|
Baseline to Day 112
|
FAST
Time Frame: Baseline to Day 112
|
Absolute change in FibroScan®- AST (FAST) score.
|
Baseline to Day 112
|
Body weight
Time Frame: Baseline to Day 112
|
Absolute change in body weight.
|
Baseline to Day 112
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Diseases
- Fatty Liver
- Non-alcoholic Fatty Liver Disease
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Sitagliptin Phosphate
Other Study ID Numbers
- DA1241_NASH_IIa
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NON-ALCOHOLIC STEATOHEPATITIS
-
Meridian Bioscience, Inc.CompletedNon-Alcoholic SteatohepatitisUnited States, France, Belgium, United Kingdom
-
Yaqrit LtdAssistance Publique - Hôpitaux de Paris; IRCCS Azienda Ospedaliero-Universitaria... and other collaboratorsWithdrawnNon-Alcoholic SteatohepatitisFrance, Italy, Portugal, Spain, Switzerland, United Kingdom
-
Enanta Pharmaceuticals, IncICON Clinical Research; Triangle BiostatisticsCompletedNon-Alcoholic SteatohepatitisUnited States, United Kingdom, New Zealand, Canada, France, Puerto Rico
-
Tanta UniversityCompletedNon Alcoholic SteatohepatitisEgypt
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnNon Alcoholic SteatohepatitisIndia
-
Tanta UniversityRecruitingNon Alcoholic SteatohepatitisEgypt
-
Sunshine Lake Pharma Co., Ltd.CompletedNon-Alcoholic SteatohepatitisChina
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingNon Alcoholic SteatohepatitisUnited States
-
GenfitTerminatedNon Alcoholic SteatohepatitisUnited States
-
Bristol-Myers SquibbCompletedNon-Alcoholic SteatohepatitisUnited States
Clinical Trials on DA-1241
-
Dong-A ST Co., Ltd.CompletedDiabetes Mellitus, Type 2United States
-
Georgetown UniversityNational Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)CompletedBreast Cancer | Ovarian CancerUnited States
-
Dong-A ST Co., Ltd.Completed
-
Dong-A ST Co., Ltd.Not yet recruiting
-
Dong-A ST Co., Ltd.RecruitingHepatitis BKorea, Republic of
-
Dong-A ST Co., Ltd.Completed
-
Dong-A ST Co., Ltd.CompletedHealthyKorea, Republic of
-
Myung-gui ChoiDong-A Pharmaceutical Co., Ltd.CompletedHealthy VolunteersKorea, Republic of
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Dong-A ST Co., Ltd.Recruiting